BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22227043)

  • 1. Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma.
    Strocchi E; Fornari F; Minguzzi M; Gramantieri L; Milazzo M; Rebuttini V; Breviglieri S; Camaggi CM; Locatelli E; Bolondi L; Comes-Franchini M
    Eur J Med Chem; 2012 Feb; 48():391-401. PubMed ID: 22227043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma.
    Harras MF; Sabour R
    Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
    Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
    J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.
    Liu JJ; Daniewski I; Ding Q; Higgins B; Ju G; Kolinsky K; Konzelmann F; Lukacs C; Pizzolato G; Rossman P; Swain A; Thakkar K; Wei CC; Miklowski D; Yang H; Yin X; Wovkulich PM
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5984-7. PubMed ID: 20832307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
    Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
    Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.
    Li X; Lu X; Xing M; Yang XH; Zhao TT; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3589-93. PubMed ID: 22572580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
    Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity.
    El-Deeb IM; Lee SH
    Bioorg Med Chem; 2010 Jun; 18(11):3961-73. PubMed ID: 20472440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
    Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of N-phenylacetyl (sulfonyl) 4,5-dihydropyrazole derivatives as potential antitumor agents.
    Liu XH; Ruan BF; Liu JX; Song BA; Jing LH; Li J; Yang Y; Zhu HL; Qi XB
    Bioorg Med Chem Lett; 2011 May; 21(10):2916-20. PubMed ID: 21486698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents.
    Liu K; Lu X; Zhang HJ; Sun J; Zhu HL
    Eur J Med Chem; 2012 Jan; 47(1):473-8. PubMed ID: 22119130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
    Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel 3,5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents.
    Bandgar BP; Totre JV; Gawande SS; Khobragade CN; Warangkar SC; Kadam PD
    Bioorg Med Chem; 2010 Aug; 18(16):6149-55. PubMed ID: 20638287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
    Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
    Hawash MM; Kahraman DC; Eren F; Cetin Atalay R; Baytas SN
    Eur J Med Chem; 2017 Mar; 129():12-26. PubMed ID: 28219046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity.
    Balbi A; Anzaldi M; Macciò C; Aiello C; Mazzei M; Gangemi R; Castagnola P; Miele M; Rosano C; Viale M
    Eur J Med Chem; 2011 Nov; 46(11):5293-309. PubMed ID: 21920636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.